Free Trial
NYSE:BMY

Bristol Myers Squibb (BMY) Stock Price, News & Analysis

Bristol Myers Squibb logo
$46.65 -0.85 (-1.78%)
Closing price 03:59 PM Eastern
Extended Trading
$46.77 +0.12 (+0.26%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Bristol Myers Squibb Stock (NYSE:BMY)

Key Stats

Today's Range
$46.31
$47.69
50-Day Range
$43.37
$48.99
52-Week Range
$42.96
$63.33
Volume
6.46 million shs
Average Volume
13.07 million shs
Market Capitalization
$94.96 billion
P/E Ratio
18.81
Dividend Yield
5.32%
Price Target
$56.38
Consensus Rating
Hold

Company Overview

Bristol Myers Squibb Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
91st Percentile Overall Score

BMY MarketRank™: 

Bristol Myers Squibb scored higher than 91% of companies evaluated by MarketBeat, and ranked 85th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bristol Myers Squibb has received a consensus rating of Hold. The company's average rating score is 2.24, and is based on 4 buy ratings, 15 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Bristol Myers Squibb has only been the subject of 4 research reports in the past 90 days.

  • Read more about Bristol Myers Squibb's stock forecast and price target.
  • Earnings Growth

    Earnings for Bristol Myers Squibb are expected to decrease by -9.64% in the coming year, from $6.74 to $6.09 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bristol Myers Squibb is 18.89, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 271.85.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bristol Myers Squibb is 18.89, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 82.97.

  • Price to Earnings Growth Ratio

    Bristol Myers Squibb has a PEG Ratio of 2.41. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Bristol Myers Squibb has a P/B Ratio of 5.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Bristol Myers Squibb's valuation and earnings.
  • Percentage of Shares Shorted

    1.46% of the float of Bristol Myers Squibb has been sold short.
  • Short Interest Ratio / Days to Cover

    Bristol Myers Squibb has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bristol Myers Squibb has recently decreased by 3.98%, indicating that investor sentiment is improving.
  • Dividend Leadership

    Bristol Myers Squibb is a leading dividend payer. It pays a dividend yield of 5.26%, putting its dividend yield in the top 25% of dividend-paying stocks.

  • Dividend Growth

    Bristol Myers Squibb has been increasing its dividend for 17 years.

  • Dividend Coverage

    The dividend payout ratio of Bristol Myers Squibb is 100.00%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Dividend Sustainability

    Based on earnings estimates, Bristol Myers Squibb will have a dividend payout ratio of 40.72% next year. This indicates that Bristol Myers Squibb will be able to sustain or increase its dividend.

  • Read more about Bristol Myers Squibb's dividend.
  • Percentage of Shares Shorted

    1.46% of the float of Bristol Myers Squibb has been sold short.
  • Short Interest Ratio / Days to Cover

    Bristol Myers Squibb has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bristol Myers Squibb has recently decreased by 3.98%, indicating that investor sentiment is improving.
  • News Sentiment

    Bristol Myers Squibb has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 38 news articles for Bristol Myers Squibb this week, compared to 52 articles on an average week.
  • Search Interest

    Only 97 people have searched for BMY on MarketBeat in the last 30 days. This is a decrease of -6% compared to the previous 30 days.
  • MarketBeat Follows

    Only 26 people have added Bristol Myers Squibb to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bristol Myers Squibb insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,667,199.00 in company stock.

  • Percentage Held by Insiders

    Only 0.07% of the stock of Bristol Myers Squibb is held by insiders.

  • Percentage Held by Institutions

    76.41% of the stock of Bristol Myers Squibb is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Bristol Myers Squibb's insider trading history.
Receive BMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bristol Myers Squibb and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BMY Stock News Headlines

Healthcare Is Sickly, But These Yields up to 7% May Still Have a Pulse
...
The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.tc pixel
What is William Blair's Forecast for BMY FY2027 Earnings?
Should You Be Impressed By Bristol-Myers Squibb Company's (NYSE:BMY) ROE?
Bristol-Myers Squibb: Not As Cheap As It Might Seem
See More Headlines

BMY Stock Analysis - Frequently Asked Questions

Bristol Myers Squibb's stock was trading at $56.56 at the start of the year. Since then, BMY stock has decreased by 17.2% and is now trading at $46.8390.

Bristol Myers Squibb Company (NYSE:BMY) issued its earnings results on Thursday, July, 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.07 by $0.39. The company's revenue for the quarter was up .6% on a year-over-year basis.
Read the conference call transcript
.

Bristol Myers Squibb's stock split before market open on Thursday, June 26th 2014.The 2-1 split was announced on Thursday, June 19th 2014. The newly minted shares were distributed to shareholders after the closing bell on Wednesday, June 25th 2014. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Bristol Myers Squibb's Board of Directors authorized a stock buyback program on Thursday, December 7th 2023, which authorizes the company to buy back $3,000,000,000 in shares, according to EventVestor. This means that the company could buy up to 2.9% of its shares through open market purchases. Shares buyback programs are usually a sign that the company's board of directors believes its shares are undervalued.

Bristol Myers Squibb subsidiaries include MyoKardia, Forbius, Celgene, IFM Therapeutics, Cormorant Pharmaceuticals, Padlock Therapeutics, Cardioxyl Pharmaceuticals, and others.

Top institutional shareholders of Bristol Myers Squibb include Vanguard Group Inc. (9.58%), State Street Corp (4.65%), Charles Schwab Investment Management Inc. (3.48%) and Geode Capital Management LLC (2.27%). Insiders that own company stock include Giovanni Caforio, David V Elkins, Samit Hirawat, Christopher S Boerner, Rupert Vessey, Theodore R Samuels II, Ann Powell, Phil M Holzer, Benjamin Hickey, Robert M Plenge and Bartie Wendy Short.
View institutional ownership trends
.

Shares of BMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bristol Myers Squibb investors own include Chevron (CVX), Comcast (CMCSA), McKesson (MCK), Charles Schwab (SCHW), Edwards Lifesciences (EW), Yum! Brands (YUM) and Toronto Dominion Bank (TD).

Company Calendar

Record date for 8/1 Dividend
7/03/2025
Ex-Dividend for 8/1 Dividend
7/03/2025
Last Earnings
7/31/2025
Dividend Payable
8/01/2025
Today
9/04/2025
Next Earnings (Estimated)
10/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceuticals
Current Symbol
NYSE:BMY
CIK
14272
Employees
34,100
Year Founded
1887

Price Target and Rating

High Price Target
$73.00
Low Price Target
$34.00
Potential Upside/Downside
+18.7%
Consensus Rating
Hold
Rating Score (0-4)
2.24
Research Coverage
21 Analysts

Profitability

EPS (Trailing Twelve Months)
$2.48
Trailing P/E Ratio
19.14
Forward P/E Ratio
7.04
P/E Growth
2.41
Net Income
-$8.95 billion
Net Margins
10.58%
Pretax Margin
13.82%
Return on Equity
80.04%
Return on Assets
14.69%

Debt

Debt-to-Equity Ratio
2.54
Current Ratio
1.21
Quick Ratio
1.11

Sales & Book Value

Annual Sales
$48.30 billion
Price / Sales
2.00
Cash Flow
$5.93 per share
Price / Cash Flow
8.01
Book Value
$8.59 per share
Price / Book
5.53

Miscellaneous

Outstanding Shares
2,035,440,000
Free Float
2,034,011,000
Market Cap
$96.64 billion
Optionable
Optionable
Beta
0.35

Social Links

10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NYSE:BMY) was last updated on 9/4/2025 by MarketBeat.com Staff
From Our Partners